GI Pancreatic - Metastatic

Localized

- NeoAdjuvant
  - IRB# 11256

Adjuvant

- IRB# 17751

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB#15588

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 16609

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 17094

Key:

- Open for Enrollment
- In Development
- Enrollment on Hold

IRB# 11256
OHSU Pancreatic IIT Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic

IRB# 17751

IRB#15588
AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

IRB# 16609
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus Pancreatic Cancer)

IRB# 17094
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus Pancreatic Cancer)

http://www.ohsu.edu/research/rsa/sos/knight.php

5/29/18